Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COMT Inhibition as a Potential Therapeutic Target Among Individuals With Comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity Disorder

NCT03904498 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT03904498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03904498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COMT Inhibition as a Potential Therapeutic Target Among Individuals With Comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity Disorder
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Completed
Start date
August 16, 2021
Completion date
March 9, 2026
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder, attention deficit hyperactivity disorder